The blood-brain barrier: Bottleneck in brain drug development

SummaryThe blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain ∼100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs. Despite the importance of the BBB to the neurotherapeutics mission, the BBB receives insufficient attention in either academic neuroscience or industry programs. The combination of so little effort in developing solutions to the BBB problem, and the minimal BBB transport of the majority of all potential CNS drugs, leads predictably to the present situation in neurotherapeutics, which is that there are few effective treatments for the majority of CNS disorders. This situation can be reversed by an accelerated effort to develop a knowledge base in the fundamental transport properties of the BBB, and the molecular and cellular biology of the brain capillary endothelium. This provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences.

[1]  W. Pardridge.  Introduction to the blood-brain barrier : methodology, biology, and pathology , 2006 .

[2]  W. Pardridge,et al.  Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  W. Pardridge,et al.  Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. , 2004, Human gene therapy.

[4]  W. Pardridge,et al.  Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer , 2004, Clinical Cancer Research.

[5]  R. Zivadinov,et al.  A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a , 2003, Journal of the Neurological Sciences.

[6]  A. Antinori,et al.  Clinical implications of HIV-1 drug resistance in the neurological compartment , 2003, Scandinavian journal of infectious diseases. Supplementum.

[7]  W. Pardridge,et al.  In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats , 2003, The journal of gene medicine.

[8]  Volker Sturm,et al.  Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma , 2003, Annals of neurology.

[9]  Bradley E. Enerson,et al.  Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. , 2003, Journal of pharmaceutical sciences.

[10]  Yi Ai,et al.  Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects , 2003, The Journal of comparative neurology.

[11]  H. Guchelaar,et al.  Direct access of drugs to the human brain after intranasal drug administration? , 2003, Neurology.

[12]  B. Williams,et al.  Assessing the Efficacy of Highly Active Antiretroviral Therapy in the Brain , 2003, Brain pathology.

[13]  H. Lee,et al.  Synthesis of Pegylated Immunonanoparticles , 2002, Pharmaceutical Research.

[14]  D. Corey,et al.  Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  W. Pardridge,et al.  Antisense gene therapy of brain cancer with an artificial virus gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Jan Born,et al.  Sniffing neuropeptides: a transnasal approach to the human brain , 2002, Nature Neuroscience.

[17]  Stefan Lundquist,et al.  The use of in vitro cell culture models for mechanistic studies and as permeability screens for the blood-brain barrier in the pharmaceutical industry--background and current status in the drug discovery process. , 2002, Vascular pharmacology.

[18]  H. Vinters,et al.  Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. , 2002, The Journal of pharmacology and experimental therapeutics.

[19]  R. Dufresne,et al.  Brain Drug Targeting: The Future of Brain Drug Development , 2002 .

[20]  W. Pardridge,et al.  Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier , 2002, Journal of neurochemistry.

[21]  H. Lee,et al.  Imaging Brain Amyloid of Alzheimer Disease in Vivo in Transgenic Mice with an Aβ Peptide Radiopharmaceutical , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  W. Pardridge,et al.  Brain-specific expression of an exogenous gene after i.v. administration , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Hynynen,et al.  Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. , 2001, Radiology.

[24]  W. Pardridge,et al.  Cloned Blood–Brain Barrier Adenosine Transporter is Identical to the Rat Concentrative Na+ Nucleoside Cotransporter CNT2 , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  W. Pardridge,et al.  Neuroprotection in Transient Focal Brain Ischemia After Delayed Intravenous Administration of Brain-Derived Neurotrophic Factor Conjugated to a Blood-Brain Barrier Drug Targeting System , 2001, Stroke.

[26]  W. Pardridge,et al.  Mediated efflux of IgG molecules from brain to blood across the blood–brain barrier , 2001, Journal of Neuroimmunology.

[27]  W. Pardridge,et al.  Rapid transferrin efflux from brain to blood across the blood–brain barrier , 2001, Journal of neurochemistry.

[28]  Q. Smith,et al.  Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique , 2001, Journal of neurochemistry.

[29]  W. Pardridge,et al.  Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin , 2001, Brain Research.

[30]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[31]  W. Pardridge,et al.  Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. , 1999, Cancer research.

[32]  W. Pardridge,et al.  Selective expression of the large neutral amino acid transporter at the blood-brain barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[34]  Alexander Sasha Rabchevsky,et al.  Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood–brain barrier without inducing reactive gliosis , 1999, Brain Research.

[35]  W. Pardridge,et al.  Neuroprotection with noninvasive neurotrophin delivery to the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Seelig,et al.  Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion , 1998, The Journal of Membrane Biology.

[37]  Q. Smith,et al.  Introduction to the Blood–Brain Barrier: Blood–brain barrier amino acid transport , 1998 .

[38]  V. Perry,et al.  CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood–brain barrier breakdown , 1998, Current Biology.

[39]  V. Perry,et al.  Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood–brain barrier breakdown in vivo , 1998, Neuroscience.

[40]  Keith L Black,et al.  Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas , 1998, Brain Research.

[41]  A. Petrillo,et al.  Blood‐Brain Barrier Disruption for the Treatment of Malignant Brain Tumors: The National Program , 1998, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[42]  D. Trombetta,et al.  Changes in the permeability of the blood-brain barrier following sodium dodecyl sulphate administration in the rat , 1997, Experimental Brain Research.

[43]  A. Blight,et al.  Spinal Cord Compression Injury in Guinea Pigs: Structural Changes of Endothelium and Its Perivascular Cell Associations after Blood–Brain Barrier Breakdown and Repair , 1997, Experimental Neurology.

[44]  J. Olson,et al.  Quantification and pharmacokinetics of blood-brain barrier disruption in humans. , 1996, Journal of neurosurgery.

[45]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  W. Pardridge,et al.  Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. , 1996, The Journal of pharmacology and experimental therapeutics.

[47]  W. Mark Saltzman,et al.  Chemotherapeutic Drugs Released from Polymers: Distribution of 1,3-bis(2-chloroethyl)-l-nitrosourea in the Rat Brain , 1996, Pharmaceutical Research.

[48]  H. Wiśniewski,et al.  Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier , 1995, Journal of neurocytology.

[49]  R. Thorne,et al.  Quantitative analysis of the olfactory pathway for drug delivery to the brain , 1995, Brain Research.

[50]  W. Pardridge,et al.  Transport of [125I]transferrin through the rat blood-brain barrier , 1995, Brain Research.

[51]  W. Mark Saltzman,et al.  Distribution of nerve growth factor following direct delivery to brain interstitium , 1995, Brain Research.

[52]  B. Öztaş,et al.  Intracarotid hypothermic saline infusion: a new method for reversible blood-brain barrier disruption in anesthetized rats , 1995, Neuroscience Letters.

[53]  P. Mcnaughton,et al.  Plasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  W. Oldendorf,et al.  Transient blood-brain barrier passage of polar compounds at low pH. , 1994, American Journal of Physiology.

[55]  M. Radeke,et al.  Distribution of Intracerebral Ventricularly Administered Neurotrophins in Rat Brain and Its Correlation with Trk Receptor Expression , 1994, Experimental Neurology.

[56]  A. Betz,et al.  Oleic acid reversibly opens the blood-brain barrier , 1991, Brain Research.

[57]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[58]  M. Hashida,et al.  The effect of polysorbate 80 on brain uptake and analgesic effect of D-kyotorphin , 1989 .

[59]  S. Rapoport,et al.  Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. , 1984, Federation proceedings.

[60]  M. Salcman,et al.  Morphologic effect of dimethyl sulfoxide on the blood-brain barrier. , 1982, Science.

[61]  Priz.-Doz. Dr. Thomas Bär.  The Vascular System of the Cerebral Cortex , 1980, Advances in Anatomy, Embryology and Cell Biology.

[62]  W. Pardridge,et al.  Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. , 1979, The Journal of clinical investigation.

[63]  W. Oldendorf,et al.  CARRIER MEDIATED BLOOD‐BRAIN BARRIER TRANSPORT OF CHOLINE AND CERTAIN CHOLINE ANALOGS , 1978, Journal of neurochemistry.

[64]  C. Patlak,et al.  Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. , 1975, The Journal of pharmacology and experimental therapeutics.

[65]  W. Oldendorf,et al.  Independent blood-brain barrier transport systems for nucleic acid precursors. , 1975, Biochimica et biophysica acta.

[66]  W H Oldendorf,et al.  Kinetics of blood-brain transport of hexoses. , 1975, Biochimica et biophysica acta.

[67]  J. M. Morrison,et al.  Ethanol enhancement of blood-brain barrier permeability to catecholamines in chicks. , 1972, European journal of pharmacology.

[68]  H. Träuble,et al.  The movement of molecules across lipid membranes: A molecular theory , 1971, The Journal of Membrane Biology.

[69]  O. Hornykiewicz,et al.  Parkinson's Disease: Activity of L-Dopa Decarboxylase in Discrete Brain Regions , 1970, Science.

[70]  W. R. Lieb,et al.  Non-stokesian nature of transverse diffusion within human red cell membranes , 2005, The Journal of Membrane Biology.

[71]  A. Billiau,et al.  Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice , 2005, Archives of Virology.

[72]  K. Kristensson,et al.  Uptake of exogenous proteins in mouse olfactory cells , 2004, Acta Neuropathologica.

[73]  A. Florence,et al.  The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80 , 2004, Cancer Chemotherapy and Pharmacology.

[74]  Y. Olsson,et al.  Structural changes in the rat brain after carotid infusions of hyperosmolar solutions , 2004, Acta Neuropathologica.

[75]  W. Pardridge,et al.  Global non-viral gene transfer to the primate brain following intravenous administration. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[76]  W. Pardridge.  Why is the global CNS pharmaceutical market so under-penetrated? , 2002, Drug discovery today.

[77]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.

[78]  W. Pardridge,et al.  Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. , 1994, The Journal of pharmacology and experimental therapeutics.

[79]  W. Wilson,et al.  Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. , 1992, Cancer research.

[80]  J. Goldberg,et al.  Effect of intracarotid etoposide on opening the blood-brain barrier. , 1984, Cancer drug delivery.